Acquired Company
AstraZeneca acquired CinCor Pharma, Inc. on 2/24/2023 for $26 per share in cash plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission, representing a total potential transaction value of up to about $1.8 billion.
CinCor Pharma Inc. is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. The companys focus is on cardiovascular, metabolic and kidney diseases. CinCor Pharma was founded by Jon Isaacsohn, M.D., and Catherine Pearce, DHSc, MBA, in 2018. Show more
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$29.06
Open
$29.06
Volume
N/A
Day Range
$29.06 - $29.06
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
12.00%
Institutional Own.
94.12%
Qtr Updated
06/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|